STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP
- 30 December 1999
- journal article
- research article
- Published by Wiley in The Prostate
Abstract
BACKGROUND In prostate cancer, we and others have observed distinct phenotypic responses to interleukin-6 (IL-6), which acts either as a paracrine growth inhibitor in the LNCaP cell line or as an autocrine growth stimulator in PC-3, DU145, and TSU cell lines. To understand the underlying mechanism responsible for this phenotypic difference, we investigated differences in the IL-6-induced Janus kinase-signal tranducers and activators of transcription (JAK-STAT) signal transduction pathway between these two phenotypes. METHODS Prostate cancer cell lines were assayed for STAT3 activity by immunoblotting, electorphoretic gel shift assays (EMSA), and a luciferase reporter assay to test for STAT3 protein expression, phosphorylation, DNA binding, and transcriptional activity. To address the physiological role of STAT3, we introduced a dominant-negative mutant of STAT3 into LNCaP cells and assayed the effects of IL-6 on cell growth of this stable transfectant by cell counting, clonogenic assays, and c-myc expression. RESULTS IL-6 induced transcriptional activity of STAT3 only in LNCaP. STAT3 was transcriptionally inactive in PC-3, TSU, and DU145 at the level of protein expression, tyrosine phosphorylation, and DNA binding/transcriptional activity, respectively. An isolated LNCaP subclone containing a dominant-negative mutant of STAT3, LNCaP-SF, did not show STAT3-DNA binding or transcriptional activity. LNCaP-SF exhibited a proliferative response to IL-6 as compared to the control LNCaP-neo clone, which underwent growth arrest. Unlike LNCaP-neo, LNCaP-SF was able form colonies and to maintain c-myc expression in the presence of IL-6. CONCLUSIONS STAT3 transcriptional activation correlates with the growth-inhibitory signal of IL-6 in LNCaP, suggesting that STAT3 transcriptional activity is an important determinant in the different phenotypic responses to IL-6 in prostate cancer. Prostate 42:88–98, 2000.Keywords
This publication has 51 references indexed in Scilit:
- Characterization of the role of IL-6 in the progression of prostate cancerThe Prostate, 1999
- Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cellsNature, 1998
- Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6International Journal of Cancer, 1996
- Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.The Journal of cell biology, 1993
- Molecular cloning and expression of an IL-6 signal transducer, gp130Cell, 1990
- AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.Proceedings of the National Academy of Sciences, 1990
- A possible autocrine role for interleukin-6 in two lymphoma cell linesBlood, 1989
- Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomasFEBS Letters, 1989
- Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6Blood, 1989
- Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNβ 2) ReceptorScience, 1988